PTAB Invalidates University of Massachusetts Patent for Vitiligo Treatment

The Patent Trial and Appeal Board (PTAB) has invalidated a University of Massachusetts patent focused on treating the skin disease vitiligo. The decision, favoring Forte Biosciences, concluded that the patent did not provide sufficient detail to describe the invention adequately or enable a skilled person to both make and use it. For further details, please refer to the original coverage on Law360.